Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Assessing drug-induced long QT and proarrhythmic risk using human stem cell-derived cardiomyocytes in a Ca2+ imaging assay: Evaluation of 28 CiPA compounds at three test sites.

Lu HR, Zeng H, Kettenhofen R, Guo L, Kopljar I, van Ammel K, Tekle F, Teisman A, Zhai J, Clouse H, Pierson J, Furniss M, Lagrutta A, Sannajust F, Gallacher DJ.

Toxicol Sci. 2019 Apr 24. pii: kfz102. doi: 10.1093/toxsci/kfz102. [Epub ahead of print]

PMID:
31020317
2.

International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.

Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L, Brock M, Lu HR, Kraushaar U, Zeng H, Shi H, Zhang X, Sawada K, Osada T, Kanda Y, Sekino Y, Pang L, Feaster TK, Kettenhofen R, Stockbridge N, Strauss DG, Gintant G.

Cell Rep. 2018 Sep 25;24(13):3582-3592. doi: 10.1016/j.celrep.2018.08.079.

3.

Synchronized electromechanical integration recording of cardiomyocytes.

Hu N, Wang T, Wan H, Zhuang L, Kettenhofen R, Zhang X, Zhang YS, Xu W, Gossmann M, Bohlen H, Hou X, Wang P.

Biosens Bioelectron. 2018 Oct 15;117:354-365. doi: 10.1016/j.bios.2018.06.017. Epub 2018 Jun 8.

PMID:
29940523
4.

Frequency-Dependent Multi-Well Cardiotoxicity Screening Enabled by Optogenetic Stimulation.

Rehnelt S, Malan D, Juhasz K, Wolters B, Doerr L, Beckler M, Kettenhofen R, Bohlen H, Bruegmann T, Sasse P.

Int J Mol Sci. 2017 Dec 6;18(12). pii: E2634. doi: 10.3390/ijms18122634.

5.

An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.

Koci B, Luerman G, Duenbostell A, Kettenhofen R, Bohlen H, Coyle L, Knight B, Ku W, Volberg W, Woska JR Jr, Brown MP.

Toxicol Appl Pharmacol. 2017 Aug 15;329:121-127. doi: 10.1016/j.taap.2017.05.023. Epub 2017 May 22.

PMID:
28546047
6.

Minimized cell usage for stem cell-derived and primary cells on an automated patch clamp system.

Becker N, Stoelzle S, Göpel S, Guinot D, Mumm P, Haarmann C, Malan D, Bohlen H, Kossolov E, Kettenhofen R, George M, Fertig N, Brüggemann A.

J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):82-7. doi: 10.1016/j.vascn.2013.03.009. Epub 2013 Apr 6.

PMID:
23567076
7.

State-of-the-Art Automated Patch Clamp Devices: Heat Activation, Action Potentials, and High Throughput in Ion Channel Screening.

Stoelzle S, Obergrussberger A, Brüggemann A, Haarmann C, George M, Kettenhofen R, Fertig N.

Front Pharmacol. 2011 Nov 24;2:76. doi: 10.3389/fphar.2011.00076. eCollection 2011.

8.

Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment.

Abassi YA, Xi B, Li N, Ouyang W, Seiler A, Watzele M, Kettenhofen R, Bohlen H, Ehlich A, Kolossov E, Wang X, Xu X.

Br J Pharmacol. 2012 Mar;165(5):1424-41. doi: 10.1111/j.1476-5381.2011.01623.x.

9.

Automated patch clamp on mESC-derived cardiomyocytes for cardiotoxicity prediction.

Stoelzle S, Haythornthwaite A, Kettenhofen R, Kolossov E, Bohlen H, George M, Brüggemann A, Fertig N.

J Biomol Screen. 2011 Sep;16(8):910-6. doi: 10.1177/1087057111413924. Epub 2011 Jul 20.

PMID:
21775699
10.

Preclinical assessment of cardiac toxicity.

Kettenhofen R, Bohlen H.

Drug Discov Today. 2008 Aug;13(15-16):702-7. doi: 10.1016/j.drudis.2008.06.011. Epub 2008 Jul 24. Review.

PMID:
18602016
11.

Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium.

Kolossov E, Bostani T, Roell W, Breitbach M, Pillekamp F, Nygren JM, Sasse P, Rubenchik O, Fries JW, Wenzel D, Geisen C, Xia Y, Lu Z, Duan Y, Kettenhofen R, Jovinge S, Bloch W, Bohlen H, Welz A, Hescheler J, Jacobsen SE, Fleischmann BK.

J Exp Med. 2006 Oct 2;203(10):2315-27. Epub 2006 Sep 5.

Supplemental Content

Loading ...
Support Center